Precigen announces clearance of IND to initiate phase 1 study for PRGN-3005 UltraCAR-T™
Precigen, an Intrexon company, announced the FDA has cleared the Investigational New Drug application for Precigen's PRGN-3005, a first-in-class investigational therapy using autologous chimeric antigen receptor T cells to treat advanced-stage platinum-resistant ovarian cancer patients. February 11, 2019